An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients

This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

Inclusion Criteria-

• Patients of any age, male or female with a clinical diagnosis of idiopathic Parkinson's disease, who participated in a previous (Phase II) clinical trial that evaluated pimavanserin
• Patients who may, in the opinion of the treating physician, benefit from continued therapy with pimavanserin
• Patient is willing and able to provide consent

Exclusion Criteria-

• Female patient of childbearing potential
• Patient has a clinically significant concurrent medical illness
• Patient is judged by the treating physician to be inappropriate for the study.